1 bination with 2',3'-dideoxycytidine or 2',3'-dideoxyinosine.

2  3'-azido-3'-deoxythymidine (AZT) plus 2',3'-dideoxyinosine.

3                           In contrast, 2',3'-dideoxyinosine, 2',3'-dideoxycytidine, and 3'-azidothymi

4 : azidothymidine; 2'3'-dideoxycytidine; 2'3'-dideoxyinosine; 2', 3'-didehydro-3'deoxythymidine; 2',3'

5  tenofovir, abacavir, 2',3'-dideoxycytidine, dideoxyinosine, and stavudine.

6 n of RNA reduction from baseline between the dideoxyinosine (ddI) and zidovudine+ddI therapeutic arms

7 onged passaging in arabinofuranyl-guanosine, dideoxyinosine (ddI), dideoxyadenosine (ddA), didehydrot

8 '-deoxythymidine [stavudine (D4T)] and 2'-3'-dideoxyinosine [didanosine (ddI)] likewise stimulated te

9 -deoxythymidine)] and didanosine [ddI (2',3'-dideoxyinosine)], in cultured human lymphoblastoid cells

10 bitor (NRTI), 2',3'-dideoxycytidine or 2',3'-dideoxyinosine, mtDNA depletion that resembled untransfe

11 -didehydro-2',3'-dideoxythymidine, and 2',3'-dideoxyinosine or affect the mtDNA recovery rate after d

12  The T69G mutation was found to confer 2',3'-dideoxyinosine resistance at the expense of fitness.

13 2'-deoxy-5-fluoro-3'-thiacytidine (FTC), and dideoxyinosine resistance, is located within this epitop

14 ination of nucleoside analogs zidovudine and dideoxyinosine with the protease inhibitor indinavir eff